Piramal Pharma Limited has successfully completed the US FDA Good Manufacturing Practices (GMP) inspection at its Aurora, Canada facility. The inspection took place from May 26 to May 30, 2025.
The US FDA conducted a thorough general GMP inspection, evaluating the facility’s compliance with stringent manufacturing standards. Piramal Pharma’s Aurora site was awarded a clean slate with zero Form 483 observations and received a No Action Indicated (NAI) designation, underscoring its commitment to excellence and regulatory compliance.
This successful inspection reinforces Piramal Pharma’s position as a leading pharmaceutical company dedicated to maintaining the highest quality standards in drug manufacturing. The company continuously strives to ensure the safety, efficacy, and quality of its products for patients worldwide.
This successful inspection reinforces Piramal Pharma’s position as a leading pharmaceutical company dedicated to maintaining the highest quality standards in drug manufacturing.
